小胶质细胞膜受体在阿尔茨海默病中的作用

doi:10.3969/j.issn.1006-9771.2020.01.011

摘要/Abstract

摘要：

β-淀粉样蛋白(Aβ)斑块沉积、神经纤维缠结和神经炎症反应是阿尔茨海默病(AD)发病的重要病理特征,小胶质细胞膜受体是介导神经炎症反应、促进Aβ清除和信号传导的关键结构。与AD相关的小胶质细胞膜受体包括髓细胞触发受体2、Toll样受体、补体系统和清道夫受体等。

关键词: 阿尔茨海默病, 小胶质细胞, 受体, 综述

Abstract:

β-amyloid (Aβ) plaque deposition, neurofibrillary tangles and neuroinflammation are important pathological features of Alzheimer's disease (AD). Microglial membrane receptors, such as triggering receptor expressed on myeloid cells 2, Toll-like receptors, complement system and scavenger receptor, play a key role that mediate neuroinflammatory responses, promote Aβ clearance and signal transduction.

Key words: Alzheimer's disease, microglia, receptor, review

中图分类号:

R749.1

林华伟,柳维林,王志福,陶静,陈立典. 小胶质细胞膜受体在阿尔茨海默病中的作用[J]. 《中国康复理论与实践》, 2020, 26(1): 62-66.

LIN Hua-wei,LIU Wei-lin,WANG Zhi-fu,TAO Jing,CHEN Li-dian. Roles of Microglial Membrane Receptors in Alzheimer's Disease (review)[J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2020, 26(1): 62-66.

参考文献 49

[1]	Blennow K, Leon M J D, Zetterberg H. Alzheimer's disease[J]. Lancet, 2006, 368(9533):387-403. pmid: 16876668
[2]	Jia J, Wei C, Chen S, et al. The cost of Alzheimer's disease in China and re-estimation of costs worldwide[J]. Alzheimers Dement, 2018, 14(4):483-491. doi: 10.1016/j.jalz.2017.12.006
[3]	Chan K Y, Wang W, Wu J J, et al. Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990-2010: a systematic review and analysis[J]. Lancet, 2013, 381(9882):2016-2023. doi: 10.1016/S0140-6736(13)60221-4 pmid: 23746902
[4]	Takahashi R H, Capetillo-Zarate E, Lin M T, et al. Co-occurrence of Alzheimer's disease β-amyloid and tau pathologies at synapses[J]. Neurobiol Aging, 2010, 31(7):1145-1152. doi: 10.1016/j.neurobiolaging.2008.07.021 pmid: 18771816
[5]	Yann V, Botond P. Binding sites of amyloid beta-peptide in cell plasma membrane and implications for Alzheimer's disease[J]. Curr Protein Pept Sci, 2004, 5(1):19-31 doi: 10.2174/1389203043486937
[6]	Gouras G K, Olsson T T, Hansson O. β-amyloid Peptides and Amyloid Plaques in Alzheimer's Disease[J]. Neurotherapeutics, 2015, 12(1):3-11. doi: 10.1007/s13311-014-0313-y
[7]	Yoshiyama Y, Higuchi M, Zhang B, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model[J]. Neuron, 2007, 53(3):337-351. pmid: 17270732
[8]	Bhaskar K, Konerth M, Kokiko-Cochran O N, et al. Regulation of tau pathology by the microglial fractalkine receptor[J]. Neuron, 2010, 68(1):19-31. doi: 10.1016/j.neuron.2010.08.023 pmid: 20920788
[9]	Kinney J W, Bemiller S M, Murtishaw A S, et al. Inflammation as a central mechanism in Alzheimer's disease[J]. Alzheimers Dement (N Y), 2018, 4:575-590.
[10]	Yoon Seong K, Tong H J. Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease[J]. Exp Mol Med, 2006, 38(4):333-347. pmid: 16953112
[11]	Tang Y, Le W. Differential roles of M1 and M2 microglia in neurodegenerative diseases[J]. Mol Neurobiol, 2016, 53(2):1181-1194. doi: 10.1007/s12035-014-9070-5 pmid: 25598354
[12]	Siamon G. Alternative activation of macrophages[J]. Nat Rev Immunol, 2003, 3(1):23-35. pmid: 12511873
[13]	Shi Y, Holtzman D M. Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight[J]. Nat Rev Immunol, 2018, 18(12):759-772. doi: 10.1038/s41577-018-0051-1
[14]	Ransohoff R M. A polarizing question: do M1 and M2 microglia exist?[J]. Nat Neurosci, 2016, 19(8):987-991. doi: 10.1038/nn.4338 pmid: 27459405
[15]	Mosser D M, Edwards J P. Exploring the full spectrum of macrophage activation[J]. Nat Rev Immunol, 2008, 8(12):958-969. doi: 10.1038/nri2448
[16]	Song W, Hooli B, Mullin K, et al. Alzheimer's disease-associated TREM2 variants exhibit either decreased or increased ligand-dependent activation[J]. Alzheimers Dement, 2016, 13(4):381-387. doi: 10.1016/j.jalz.2016.07.004
[17]	Giuseppina S, Paola P, Margherita M, et al. Distribution and signaling of TREM2/DAP12, the receptor system mutated in human polycystic lipomembraneous osteodysplasia with sclerosing leukoencephalopathy dementia[J]. Eur J Neurosci, 2015, 20(10):2617-2628. doi: 10.1111/ejn.2004.20.issue-10
[18]	Yuan P, Condello C, Keene C D, et al. TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy[J]. Neuron, 2016, 90(4):724-739. doi: 10.1016/j.neuron.2016.05.003
[19]	Pietro Luigi P, Yaming W, Elena F, et al. TREM2 sustains microglial expansion during aging and response to demyelination[J]. J Clin Invest, 2015, 125(5):2161-2170. doi: 10.1172/JCI77983
[20]	Jay T R, Hirsch A M, Broihier M L, et al. Disease progression-dependent effects of TREM2 deficiency in a mouse model of Alzheimer's disease[J]. J Neurosci, 2016, 37(3):637-647. doi: 10.1523/JNEUROSCI.2110-16.2016
[21]	Lehnardt S. Innate immunity and neuroinflammation in the CNS: the role of microglia in Toll-like receptor-mediated neuronal injury[J]. Glia, 2010, 58(3):253-263. doi: 10.1002/glia.20928 pmid: 19705460
[22]	Bader S, Mühlhauser F, Brechtel K. Dose-dependent activation of microglial cells by Toll-like receptor agonists alone and in combination[J]. J Neuroimmunol, 2005, 159(1):87-96. doi: 10.1016/j.jneuroim.2004.10.005
[23]	Fassbender K, Walter S, Kühl S, et al. The LPS receptor (CD14) links innate immunity with Alzheimer's disease[J]. FASEB J, 2004, 18(1):203-205. pmid: 14597556
[24]	Guillot-Sestier M V, Town T. Let's make microglia great again in neurodegenerative disorders[J]. J Neural Transm (Vienna), 2018, 125(5):751-770.
[25]	Mcdonald C L, Hennessy E, Rubio-Araiz A, et al. Inhibiting TLR2 activation attenuates amyloid accumulation and glial activation in a mouse model of Alzheimer's disease[J]. Brain Behav Immun, 2016, 58:191-200. doi: 10.1016/j.bbi.2016.07.143
[26]	Wendeln A C, Degenhardt K, Kaurani L, et al. Innate immune memory in the brain shapes neurological disease hallmarks[J]. Nature, 2018, 556(7701):332-338. doi: 10.1038/s41586-018-0023-4
[27]	Walter S, Letiembre M, Liu Y, et al. Role of the Toll-like receptor 4 in neuroinflammation in Alzheimer's disease[J]. Cell Physiol Biochem, 2007, 20(6):947-956. pmid: 17982277
[28]	Li X, Melief E, Postupna N, et al. Prostaglandin E₂ receptor subtype 2 regulation of scavenger receptor CD₃₆ modulates microglial Aβ₄₂ phagocytosis[J]. Am J Pathol, 2015, 185(1):230-239. doi: 10.1016/j.ajpath.2014.09.016
[29]	Hong S, Beja-Glasser V F, Nfonoyim B M, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models[J]. Science, 2016, 352(6286):712-716. doi: 10.1126/science.aad8373
[30]	Hongjun F, Bin L, Frost J L, et al. Complement component C3 and complement receptor type 3 contribute to the phagocytosis and clearance of fibrillar Aβ by microglia[J]. Glia, 2012, 60(6):993-1003. doi: 10.1002/glia.22331 pmid: 22438044
[31]	Chakrabarty P, Li A, Ceballos-Diaz C, et al. IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior[J]. Neuron, 2015, 85(3):519-533. doi: 10.1016/j.neuron.2014.11.020 pmid: 25619653
[32]	Lian H, Litvinchuk A, Chiang A C, et al. Astrocyte-microglia cross talk through complement activation modulates amyloid pathology in mouse models of Alzheimer's disease[J]. J Neurosci, 2016, 36(2):577-589. doi: 10.1523/JNEUROSCI.2117-15.2016
[33]	Woodruff T M, Ager R R, Tenner A J, et al. The role of the complement system and the activation fragment C_5a in the central nervous system[J]. Neuromolecular Med, 2010, 12(2):179-192. doi: 10.1007/s12017-009-8085-y
[34]	Ager R R, Fonseca M I, Chu S H, et al. Microglial C_5aR (CD₈₈) expression correlates with amyloid-beta deposition in murine models of Alzheimer's disease[J]. J Neurochem, 2010, 113(2):389-401. doi: 10.1111/jnc.2010.113.issue-2
[35]	Fonseca M I, Ager R R, Chu S H. Treatment with a C_5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease[J]. J Immunol, 2009, 183(2):1375-1383. doi: 10.4049/jimmunol.0901005 pmid: 19561098
[36]	Krieger M. The other side of scavenger receptors: pattern recognition for host defense[J]. Curr Opin Lipidol, 1997, 8(5):275-280. pmid: 9335951
[37]	Godoy B, Murgas P, Tichauer J, et al. Scavenger receptor class A ligands induce secretion of IL1β and exert a modulatory effect on the inflammatory activation of astrocytes in culture[J]. J Neuroimmunol, 2012, 251(1-2):6-13. doi: 10.1016/j.jneuroim.2012.06.004 pmid: 22743055
[38]	Coraci I S, Husemann J, Berman J W, et al. CD₃₆, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to β-amyloid fibrils[J]. Am J Pathol, 2002, 160(1):101-112. pmid: 11786404
[39]	Yang C N, Shiao Y J, Shie F S, et al. Mechanism mediating oligomeric Abeta clearance by naive primary microglia[J]. Neurobiol Dis, 2011, 42(3):221-230. doi: 10.1016/j.nbd.2011.01.005
[40]	Frenkel D, Wilkinson K, Zhao L, et al. Scara1 deficiency impairs clearance of soluble amyloid-β by mononuclear phagocytes and accelerates Alzheimer's-like disease progression[J]. Nat Commun, 2013, 4:2030. doi: 10.1038/ncomms3030 pmid: 23799536
[41]	Maria E B, Meera E H, Douglas R M, et al. A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation[J]. J Neurosci, 2003, 23(7):2665-2674. doi: 10.1523/JNEUROSCI.23-07-02665.2003
[42]	Mitsugu Y, Taizo I, Angelika G, et al. PPARγ/RXRα-induced and CD₃₆-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice[J]. J Neurosci, 2012, 32(48):17321-17331. doi: 10.1523/JNEUROSCI.1569-12.2012
[43]	Wang C Y, Wang Z Y, Xie J W, et al. CD₃₆ upregulation mediated by intranasal LV-NRF2 treatment mitigates hypoxia-induced progression of Alzheimer's-like pathogenesis[J]. Antioxid Redox Signal, 2014, 21(16):2208-2230. doi: 10.1089/ars.2014.5845
[44]	Akirav E M, Paula P H, Justin G, et al. RAGE expression in human T cells: a link between environmental factors and adaptive immune responses[J]. PLoS One, 2012, 7(4):e34698. doi: 10.1371/journal.pone.0034698
[45]	Choi B R, Cho W H, Kim J, et al. Increased expression of the receptor for advanced glycation end products in neurons and astrocytes in a triple transgenic mouse model of Alzheimer's disease[J]. Exp Mol Med, 2014, 46(2):e75. doi: 10.1038/emm.2013.147
[46]	Yan S D, Chen X, Fu J, et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease[J]. Nature, 1996, 382(6593):685-691. pmid: 8751438
[47]	Fang F, Lih-Fen L, Shiqiang Y, et al. RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease[J]. FASEB J, 2010, 24(4):1043-1055. doi: 10.1096/fj.09-139634 pmid: 19906677
[48]	Nicola O, Camilla B, Alfredo R, et al. Microglial receptor for advanced glycation end product-dependent signal pathway drives beta-amyloid-induced synaptic depression and long-term depression impairment in entorhinal cortex[J]. J Neurosci, 2010, 30(34):11414-11425. doi: 10.1523/JNEUROSCI.2127-10.2010
[49]	Rashid D, Itender S, Abhay P S, et al. A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease[J]. J Clin Invest, 2012, 122(4):1377-1392. doi: 10.1172/JCI58642